PTCSC3

Summary

PTCSC3 (papillary thyroid carcinoma susceptibility candidate 3, HGNC:43959) is a long non-coding RNA gene on chromosome 14q13.3.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:43959
Approved symbol	PTCSC3
Name	papillary thyroid carcinoma susceptibility candidate 3
Location	14q13.3
Locus type	RNA, long non-coding
Status	Approved
Ensembl gene	ENSG00000259104
Ensembl biotype	lncRNA
OMIM	614821
Entrez	100886964
RNAcentral	URS00026A19EA — lncRNA, 2043 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 lncRNA

ENST00000556013, ENST00000706908, ENST00000706909, ENST00000706910, ENST00000818560, ENST00000818561, ENST00000818562, ENST00000818563

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000556013 — 4 exons

Exon	Start	End
ENSE00002448729	36134890	36136356
ENSE00002513411	36153804	36153894
ENSE00002513918	36176298	36176722
ENSE00003997423	36162624	36162683

Expression profiles

Bgee: expression breadth ubiquitous, 112 present calls, max score 95.18.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3535 / max 116.0117, expressed in 18 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
142910	0.0735	12
142913	0.0703	11
142906	0.0422	10
142908	0.0385	6
142907	0.0373	4
142911	0.0326	10
142909	0.0246	8
142912	0.0217	9
142914	0.0128	5

Top tissues by expression

112 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left lobe of thyroid gland	UBERON:0001120	95.18	gold quality
right lobe of thyroid gland	UBERON:0001119	95.00	gold quality
thyroid gland	UBERON:0002046	94.94	gold quality
corpus callosum	UBERON:0002336	90.28	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.02	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.03	gold quality
leukocyte	CL:0000738	66.57	gold quality
monocyte	CL:0000576	66.32	gold quality
adult mammalian kidney	UBERON:0000082	65.75	gold quality
kidney	UBERON:0002113	65.42	gold quality
cortex of kidney	UBERON:0001225	63.57	gold quality
ganglionic eminence	UBERON:0004023	63.47	gold quality
blood	UBERON:0000178	59.40	gold quality
prefrontal cortex	UBERON:0000451	58.02	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	57.89	gold quality
primary visual cortex	UBERON:0002436	57.77	gold quality
calcaneal tendon	UBERON:0003701	56.78	gold quality
rectum	UBERON:0001052	56.77	gold quality
metanephros cortex	UBERON:0010533	56.73	gold quality
placenta	UBERON:0001987	56.42	gold quality
superior frontal gyrus	UBERON:0002661	56.03	gold quality
right lung	UBERON:0002167	55.53	gold quality
lung	UBERON:0002048	55.28	gold quality
muscle tissue	UBERON:0002385	55.25	gold quality
duodenum	UBERON:0002114	54.84	gold quality
islet of Langerhans	UBERON:0000006	54.17	gold quality
substantia nigra	UBERON:0002038	53.47	gold quality
upper lobe of left lung	UBERON:0008952	53.43	gold quality
liver	UBERON:0002107	52.98	gold quality
multicellular organism	UBERON:0000468	52.86	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	2.82

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 13)

• Data suggest that single nucleotide polymorphism rs944289 predisposes to papillary thyroid carcinoma through a long intergenic noncoding RNA gene papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) that was characterized of a tumor suppressor. (PMID:22586128)
• rs944289 on chromosome 14q13.3 has a role in both malignant and benign thyroid tumors in the Japanese population (PMID:25562676)
• PTCSC3 downregulates S100A4, leading to a reduction in cell motility and invasiveness. We propose that PTCSC3 impacts papillary thyroid cancer predisposition and carcinogenesis through the S100A4 pathway. (PMID:26274343)
• Identify novel associations between large-vessel ischemic stroke and polymorphisms in the PTCSC3 gene. (PMID:27025970)
• LncRNA PTCSC3 inhibits the proliferation and migration of glioma cells and suppresses Wnt/beta-catenin signaling pathway by targeting LRP6 (PMID:28187755)
• The signaling PTCSC3-miR-574-5p-SCAI-Wnt/beta-catenin mediated the proliferation and migration of PTC-1 cells, which was vital for the further papillary thyroid carcinoma therapy and prognosis. (PMID:28513866)
• LncRNA PTCSC3 was low-expressed in anaplastic thyroid cancer (ATC) tissues and cells. Over-expressed PTCSC3 inhibited the drug resistance of ATC to doxorubicin. PTCSC3 negatively regulated STAT3, and STAT3 promoted expression of INO80. PTCSC3 regulated INO80 through STAT3. PTCSC3 suppressed stem cells properties and drug resistance of ATC to doxorubicin. (PMID:29561707)
• LncRNA PTCSC3 inhibits triple-negative breast cancer cell proliferation by downregulating lncRNA H19. (PMID:31026090)
• LncRNA PTCSC3 inhibits cell proliferation in laryngeal squamous cell carcinoma by down-regulating lncRNA HOTAIR. (PMID:31171714)
• lncRNA PTCSC3 may regulate the proliferation of periodontal ligament stem cells and TLR4 expression to improve periodontitis (PMID:31196168)
• LncRNA PTCSC3 inhibits the proliferation, invasion and migration of cervical cancer cells via sponging miR-574-5p. (PMID:31587336)
• LncRNA PTCSC3 Is a Biomarker for the Treatment and Prognosis of Gastric Cancer. (PMID:31702383)
• PTCSC3-mediated glycolysis suppresses thyroid cancer progression via interfering with PGK1 degradation. (PMID:34337858)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.